If your email program has trouble displaying this email, view as a webpage. Recently Posted Guidance Documents 1/26/2022 - Good ANDA Submission Practices Guidance for Industry 1/26/2022 - Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments: Guidance for Industry 1/26/2022 - Principles of Premarket Pathways for Combination Products: Guidance for Industry and FDA Staff 1/26/2022 - Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders 1/26/2022 - Patient Engagement in the Design and Conduct of Medical Device Clinical Studies: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders 1/25/2022 - Revising ANDA Labeling Following Revision of the RLD Labeling Guidance for Industry: Draft Guidance for Industry 1/21/2022 - Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH): Guidance for Industry Technical Specifications Document 1/21/2022 - Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Draft Guidance for Industry, Investigators, and Other Stakeholders Guidance Document Search Search all FDA official guidance documents and other regulatory guidance

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA